Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 5:56:101565.
doi: 10.1016/j.ijcha.2024.101565. eCollection 2025 Feb.

Direct oral anticoagulants in deep vein thrombosis associated with inferior vena cava agenesis: A report of three cases and a systematic review

Nicola Osti  1 , Vito Racanelli  2   3 , Nicola Susca  2 , Nicola Martinelli  4 , Alberto Maino  2   3
Affiliations
Review

Direct oral anticoagulants in deep vein thrombosis associated with inferior vena cava agenesis: A report of three cases and a systematic review

Nicola Osti et al. Int J Cardiol Heart Vasc. .

Abstract

Background: Inferior vena cava agenesis (IVCA) is a rare vascular abnormality characterised by the absence of one or more segments of the inferior vena cava and represents an underestimated cause of deep vein thrombosis (DVT). Given the very low prevalence of this condition and the lack of clinical trials, there is no consensus about the optimal anticoagulation strategy in IVCA-associated DVT.

Objectives: To investigate efficacy and safety of direct oral anticoagulants (DOACs) in IVCA-associated DVT.

Methods: We described three patients with IVCA-associated DVT followed at our Institution and treated with DOACs. Then, we performed a systematic review of the literature for ICVA-associated DVT treated with DOACs.

Results: In addition to our 3 cases, we found data from 19 publications for a total of 30 patients with IVCA-associated DVT treated with DOACs (24 subjects treated with rivaroxaban, 8 with apixaban, and one with dabigatran). Most patients were males (72.7 %) with a median age at DVT onset of 26.0 years (min-max range 13-64 years). The majority of DVT events were unprovoked (76.0 %). The standard thrombophilia tests were mainly negative. The median follow-up period during DOAC therapy was 1.0 years (min-max range 0-10 years), with one recurrent splanchnic vein thrombosis reported and no haemorrhagic events.

Conclusions: IVCA is a rare cause of DVT, which should be suspected in young adults with unprovoked DVT. Although future studies are needed, available data may support the use of DOACs in IVCA-associated DVT, with a reassuring profile of both efficacy and safety.

Keywords: Deep vein thrombosis; Direct oral anticoagulants; Inferior vena cava agenesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Coronal reconstruction of abdominal and thoracic CT scan of patient #2. Red arrow: abdominal aorta; green arrows: dilated and tortuous azygos veins with the absence of inferior vena cava; yellow arrow: dilated superior vena cava with drainage of hepatic flow.
Fig. 2
Fig. 2
Flowchart of literature search and study selection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Spentzouris G., Zandian A., Cesmebasi A., Kinsella C.R., Muhleman M., Mirzayan N., Shirak M., Tubbs R.S., Shaffer K., Loukas M. The clinical anatomy of the inferior vena cava: a review of common congenital anomalies and considerations for clinicians. Clin Anat. 2014 Nov;27(8):1234–1243. doi: 10.1002/ca.22445. - DOI - PubMed
    1. Bravo-Pérez C, Blanco A, Revilla N, Cobos J, Salgado-Parente A, Asenjo S, Méndez R, Marti-Bonmati L, Bonanad S, Albillos JC, Castro N, Marcellini S, López Sala P, Lasa M, Bastida JM, Infante MS, Corral MA, Pagan J, Llamas P, Rodríguez-Sevilla JJ, Rodríguez-Alen A, Sevivas TS, Morello D, Villar CG, Lojo S, Marco A, Simioni P, Vicente V, Lozano ML, de la Morena-Barrio ME, García-Santos JM, Corral J; IVC Agenesis Study Group. Thrombotic risk and features of patients with inferior vena cava agenesis: a multicentre, retrospective, observational study. Lancet Haematol. 2024 Jun 12:S2352-3026(24)00138-8. https://doi.org/10.1016/S2352-3026(24)00138-8. - PubMed
    1. de la Morena-Barrio M.E., Gindele R., Bravo-Pérez C., et al. High penetrance of inferior vena cava system atresia in severe thrombophilia caused by homozygous antithrombin Budapest 3 variant: description of a new syndrome. Am J Hematol. 2021;96:1363–1373. doi: 10.1002/ajh.26304. - DOI - PubMed
    1. Saab K., Brahmandam A.S., Brackett A.L., Desai M.M., Dardik A., Guzman R.J., Chaar C.I.O. Systematic review of inferior vena cava atresia. J. Vasc Surg. Venous Lymphat Disord. 2023 Nov;11(6):1253–1264. doi: 10.1016/j.jvsv.2023.07.002. - DOI - PubMed
    1. Moragón-Ledesma S., Galeano-Valle F., Calleja-Cartón E., Del-Toro-Cervera J., Demelo-Rodríguez P. Bilateral deep vein thrombosis, vena cava agenesis, and renal abnormalities: kilt syndrome-a case report and literature review. J. Cardiovasc Transl. Res. 2020 Aug;13(4):629–631. doi: 10.1007/s12265-019-09935-9. - DOI - PubMed

LinkOut - more resources